What you will learn
By the end of this topic, you should be able to distinguish surveillance from vigilance; build a risk-based post-market plan; integrate multiple data sources; triage complaints and incidents; detect and investigate signals; support timely regulatory reporting; produce periodic outputs; coordinate corrective action; and feed field evidence back into risk, clinical evaluation and design.
The post-market surveillance and vigilance role
Post-market surveillance systematically gathers and evaluates experience from released devices. Vigilance manages reportable serious incidents, trends and safety corrective action under applicable rules. Specialists connect these activities so that urgent cases receive timely action while aggregate data reveals slower patterns.
System designer
Define sources, methods, responsibilities, thresholds and outputs.
Case coordinator
Drive intake, triage, investigation, reportability and deadlines.
Signal analyst
Detect changes in frequency, severity, population or failure mode.
Lifecycle connector
Return field knowledge to risk, clinical, quality and development teams.
Build a proactive, risk-based PMS system
The PMS plan should define the device scope, markets, data sources, methods, responsibilities, frequencies, indicators, thresholds and required reports. It should be proportionate to risk, novelty, usage, population and remaining uncertainties—not limited to waiting for complaints. Start with MTL-127 — Post-market Support.
Combine sources before drawing conclusions
- Complaints, service records, returns and technical investigations.
- Serious incidents, adverse-event databases and field safety actions.
- Usage, performance and cybersecurity monitoring where justified.
- Post-market clinical or performance follow-up.
- Literature, registries, surveys and user feedback.
- Supplier notices and information about similar devices.
- Sales, installed-base and exposure data needed for meaningful rates.
Each source has blind spots. Define data quality, coding, deduplication and denominators so comparisons are interpretable.
Triage protects both deadlines and patients
Capture enough information to identify the device and version, event, outcome, reporter, dates and context. Screen promptly for death, serious deterioration, public-health threat, cybersecurity impact, recurrence and need for containment. Reportability decisions require documented rationale and market-specific review; a complaint can be non-reportable yet still safety-significant.
Detect signals, then investigate their meaning
Trend by device family, version, lot, geography, user, environment and failure mode where these distinctions are meaningful. Statistical thresholds support judgement; they do not replace it.
Control vigilance decisions and regulatory reporting
Maintain market-specific criteria, timelines, submission routes and follow-up obligations. Record when the organisation became aware, what facts were available, how causality and seriousness were assessed, and why the event was or was not reportable. Coordinate consistent information across authorities without delaying an initial report while an investigation continues.
Periodic outputs should explain benefit–risk, not just count cases
Post-market surveillance reports, periodic safety update reports and management reviews should synthesise exposure, complaints, serious incidents, trends, corrective actions, literature, follow-up findings and conclusions. Compare current performance with expected rates and the accepted benefit–risk determination. MTL-326 — EU Post-market Surveillance, PMCF/PMPF and PSUR Guidance explains the EU framework.
Translate findings into proportionate action
Actions may include enhanced monitoring, customer communication, training, labelling, service instruction, software update, design change, CAPA, field safety corrective action or recall. Define affected configurations and populations, assess new risks introduced by the action, verify effectiveness and meet notification requirements.
Close the loop into development evidence
Update the risk-management file, clinical or performance evaluation, usability engineering, cybersecurity assessment, product requirements and verification as relevant. Revisit occurrence estimates and known side effects using real-world exposure. Post-market information should influence the next release and future product architecture, not remain in an annual report.
Govern decisions across functions and borders
Define ownership between complaint handling, vigilance, regulatory, medical, quality, engineering, cybersecurity, service and local representatives. Use a shared device and event vocabulary, controlled clocks, competent review and escalation for disagreement. Audit hand-offs because delayed information is a common source of missed reporting.
Common misconceptions
“No complaints means no problem.”
Under-reporting, low use, poor detectability or fragmented data can hide risk.
“Vigilance begins after the investigation.”
Initial reporting deadlines may run before root cause is known; follow-up reports can add evidence.
“PMS is an annual report.”
The report is an output of a continuous system for gathering, evaluating and acting on information.
Authoritative starting points
Post-market evidence must change decisions
Gather broadly, triage promptly, analyse in context and feed every meaningful signal back into product safety and performance.